Search by Drug Name or NDC

    NDC 63824-0943-02 Mucinex Childrens 5; 100 mg/1; mg/1 Details

    Mucinex Childrens 5; 100 mg/1; mg/1

    Mucinex Childrens is a ORAL GRANULE in the HUMAN OTC DRUG category. It is labeled and distributed by RB Health (US) LLC. The primary component is DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN.

    Product Information

    NDC 63824-0943
    Product ID 63824-943_a3080d71-61a2-4814-a63e-3fe61121ab26
    Associated GPIs
    GCN Sequence Number 063317
    GCN Sequence Number Description guaifenesin/dextromethorphan GRAN PACK 100MG-5MG ORAL
    HIC3 B3T
    HIC3 Description NON-OPIOID ANTITUSSIVE AND EXPECTORANT COMBINATION
    GCN 99068
    HICL Sequence Number 000223
    HICL Sequence Number Description GUAIFENESIN/DEXTROMETHORPHAN HBR
    Brand/Generic Brand
    Proprietary Name Mucinex Childrens
    Proprietary Name Suffix Cough and Chest Congestion Mini-Melts Orange Creme
    Non-Proprietary Name Dextromethorphan Hydrobromide and Guaifenesin
    Product Type HUMAN OTC DRUG
    Dosage Form GRANULE
    Route ORAL
    Active Ingredient Strength 5; 100
    Active Ingredient Units mg/1; mg/1
    Substance Name DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN
    Labeler Name RB Health (US) LLC
    Pharmaceutical Class Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Ant
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2024-12-31

    Package

    NDC 63824-0943-02 (63824094302)

    NDC Package Code 63824-943-02
    Billing NDC 63824094302
    Package 2 PACKET in 1 PACKAGE (63824-943-02) / 1 GRANULE in 1 PACKET
    Marketing Start Date 2022-01-27
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 66543190-1d3d-4259-ae73-d366ecbf9e52 Details

    Revised: 1/2022